Endothelium-derived relaxing factor was identified as nitric oxide (NO) or a closely related molecule synthesized from arginine by nitric oxide synthase (NOS) (1) . NO is a short-lived gas that is implicated in the regulation of mammalian blood vessels and other systems (2) . NOS exists in 3 isozymic forms including 2 constitutive Cat+ dependent isoforms (cNOS) from endothelial cells and neurons and a Cat+-independent isoform (iNOS) that is induced by endotoxin or cytokines in several cells such as macrophages and endothelial cells (3). While NO produced by cNOS may have physiological roles, the overproduction of NO by iNOS may have a causal relationship with inflammatory vasodilation or septic shock (4). Therefore, specific inhibitors of iNOS may have some therapeutic value in these pathological condi tions (5). While arginine analog inhibitors of NOS such as NG-nitro-L-arginine methyl ester (L-NAME) inhibit both cNOS and iNOS, aminoguanidine is proposed as a preferential inhibitor of iNOS (6). By using NOS inhibitors (7 -10), we showed that NO is involved in the plasma leakage induced by the lipopolysaccharide (LPS) from Salmonella typhimurium and 5-hydroxytryptamine (5-HT) but not by platelet activating factor (PAF) in the mouse skin. In addition, we found that aminoguanidine inhibited the LPS-induced plasma extravasation but not 5-HT-induced dye leakage. This finding suggests that NO produced by iNOS plays a role in the LPS-induced increase in vascular permeabil ity as a toxin. Recently, S-ethylisothiourea (EIT) has been shown to be a potent selective inhibitor of iNOS in vitro (11, 12). Another isothiourea analog, S-methylisothio urea, has been shown to exert beneficial effects in rodent models of septic shock (13). Therefore, the purpose of this study is to examine whether EIT mimics amino guanidine in the differential inhibitory effect on the dye leakage induced by LPS, 5-HT as well as PAF.
Changes in the dermal vascular permeability induced by LPS, 5-HT and PAF were investigated by determining Pontamine sky blue leakage in the mouse skin as described previously (7). Male ddY strain mice weighing about 35 g (Sankyo Laboratory Service, Tokyo) were in jected i.v. with Pontamine sky blue (50 mg/kg). Five minutes later, LPS (400 pg/site), 5-HT (0.1 ug/site) or PAF (0.1 pg/site) dissolved in 0.1 ml saline was injected s.c. in the back of the mouse, and 0.1 ml saline was given s.c. instead of proinflammatory stimuli as a control. NOS inhibitors were injected i.v. immediately before dye injec tion. After 1 hr (for 5-HT and PAF) or 2 hr (for LPS), the mice were killed by cervical dislocation, and then the stained injection site of the dorsal skin was excised. The dye was extracted with a mixture of acetone and 0.5% sodium sulfate (14:6, v/v), determined colorimetrically at 590 nm.
Aminoguanidine hemisulfate, 5-HT creatinine sulfate, indomethacin, LPS from Salmonella typhimurium and L-NAME . HCl were purchased from Sigma (St. Louis, MO, USA); 1-O-hexadecyl-2-O-acetyl-sn-glycero-3-phos phocholine (PAF) from Nova Biochem (Laufelfingen,
HCl from Nacalai Tesque (Kyoto). EIT was synthesized as described previ ously (12). The other drugs were available from commer cial sources. All the doses refer to the salt form of the drugs. EIT (5 and 10 ug/kg) decreased LPS-induced plasma leakage dose-dependently (Fig. 1) . Whereas the lower dose of EIT did not inhibit the 5-HT-induced dye leak age, the higher dose caused a slight inhibition. Amino guanidine, a putative iNOS inhibitor, inhibited plasma extravasation induced by LPS but not that by 5-HT, whereas L-NAME, a nonspecific NOS inhibitor, inhibited the plasma extravasation elicited by 5-HT more efficiently than that induced by LPS (Table 1) .
Dye leakage induced by PAF was not inhibited by any of the 3 NOS inhibitors. These findings confirm our previous reports that NO is involved in the dye leakage induced by LPS and 5-HT but not that by PAF (7-10). Presumably, iNOS is involved in the NO production in LPS-induced plasma extravasation, while cNOS plays a role in produc tion of NO by 5-HT. The differential inhibition by the 5 ,ug/kg dose of EIT of the plasma leakage elicited by LPS and 5-HT was similar to the mode of inhibition by aminoguanidine rather than that by L-NAME in that EIT inhibited the effect of LPS more efficiently than that of 5-HT (Table 1) . The difference of the doses employed in dicates that EIT was about 1000 times more potent than aminoguanidine in inhibiting the LPS-induced dye leak age. This reflects the difference in the inhibitory potency on iNOS in vitro between the 2 drugs (11). We propose that comparison of the inhibition of LPS-induced dye leakage by a drug against its inhibition of 5-HT-induced dye extravasation may be a good parameter for screening potential iNOS inhibitors in vivo. As EIT (10 pg/kg) suppressed the effect of 5-HT slightly, the iNOS selectivi ty of EIT may decrease along with an increasing dose. Actually, Southan et al. (14) reported that EIT is a potent inhibitor of both cNOS and iNOS, although some inves tigators proposed that EIT is an iNOS-specific inhibitor (11, 12). At 2 hr but not 1 hr after i.v. injection of a 10 pg/kg dose of EIT, EIT by itself induced a faint but generalized dye leakage in the skin (Fig. 1 ) that was not confined to the site of s.c. injection of proinflammatory stimuli. Prostaglandins or histamine would not play roles as mediators, because indomethacin or diphenhydramine did not inhibit the effect of EIT alone ( Table 2 ). The dose of indomethacin is sufficient for inhibition of cyclooxy genase (15), and we confirmed that this dose of diphen hydramine inhibited the histamine (1 pg/site)-induced dye leakage completely (data not shown). At present, the mechanism of the EIT-induced delayed increase in vascu lar permeability is not known; however, a high dose of EIT may directly injure endothelial cells or increase the intravascular volume of the skin. The dye leakage in duced by EIT by itself may hamper the proper evaluation of the potency of EIT in inhibiting the LPS-induced vas cular permeability and decrease the usefulness of EIT as a possible drug for endotoxin shock.
